Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26316505 | 0.80 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL13104148 | 0.80 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL10794688 | 0.78 | TSHR (0.46) | TSHRTDP1 | |
| SCHEMBL17793493 | 0.75 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL18589318 | 0.75 | TSHR (0.32) | TSHRTDP1 | |
| SCHEMBL14204 | 0.73 | — | — | |
| SCHEMBL9168093 | 0.73 | — | — | |
| SCHEMBL19504328 | 0.73 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL13173609 | 0.73 | TSHR (0.35) | TSHRTDP1 | |
| SCHEMBL14726747 | 0.73 | TSHR (0.30) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230269999-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-08-24 | — | — | US | disclosed |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-27 | — | — | US | disclosed |
| US-8772301-B2 | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof | SUNOVION PHARMACEUTICALS, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140178582-A1 | COMPOSITE MEMBRANE FORMED FROM POLYMER BLEND INCLUDING SELF-ASSEMBLING BLOCK COPOLYMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319380-A1 | Compounds for Treating Disorders Mediated by Metabotropic Glutamate Receptor 5, and Methods of Use Thereof | GRM5, GRM2, GRM1 | TSHR 1410/4885TDP1 1917/4885 |
| US-20230269999-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ACAT1, ACMSD, SLC25A21 | TSHR 4612/4885TDP1 2690/4885 |
| US-20140349992-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TSHR 1410/4885TDP1 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.